Biotechnology company Aerpio Therapeutics has advanced its novel small molecule drug for diabetic macular edema (DME) into a Phase 1b/2a clinical trial (dose-range finding in patients). Aerpio’s lead compound, AKB-9778 affects the Ang/Tie pathway, an exciting and very promising target in diabetic macular edema.
Dr. Ng serves on the clinical advisory board of Aerpio Therapeutics.
For more information, please go to http://www.aerpio.com/news/